Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

White coat hypertension may be an initial sign of the metabolic syndrome.

Helvaci MR, Kaya H, Gundogdu M.

Acta Med Indones. 2012 Jul;44(3):222-7.

2.

White coat hypertension in definition of metabolic syndrome.

Helvaci MR, Kaya H, Seyhanli M, Yalcin A.

Int Heart J. 2008 Jul;49(4):449-57.

3.

Treatment of white coat hypertension with metformin.

Helvaci MR, Sevinc A, Camci C, Yalcin A.

Int Heart J. 2008 Nov;49(6):671-9.

4.

Gender differences in patients with metabolic syndrome in coronary artery interventions.

Rami Helvaci M, Kaya H, Gundogdu M.

Med Glas (Zenica). 2013 Feb;10(1):75-80.

PMID:
23348166
5.

What is the relationship between white coat hypertension and dyslipidemia?

Helvaci MR, Kaya H, Duru M, Yalcin A.

Int Heart J. 2008 Jan;49(1):87-93.

6.

Prevalence of white coat hypertension in underweight and overweight subjects.

Helvaci MR, Kaya H, Yalcin A, Kuvandik G.

Int Heart J. 2007 Sep;48(5):605-13.

7.

[Situation of impaired glucose regulation and metabolic syndrome in overweight or obesity adolescent students in Dongguan city].

Peng YQ, Nie WM, Chen JG, Tang HM, Cao T, Lin YX.

Zhonghua Yu Fang Yi Xue Za Zhi. 2009 Jun;43(6):495-500. Chinese.

PMID:
19950716
8.

Metformin and parameters of physical health.

Helvaci MR, Kaya H, Borazan A, Ozer C, Seyhanli M, Yalcin A.

Intern Med. 2008;47(8):697-703. Epub 2008 Apr 16.

10.
11.

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483.

PMID:
16861090
12.

Prevalence of dyslipidemia and associated risk factors among Turkish adults: Trabzon lipid study.

Erem C, Hacihasanoglu A, Deger O, Kocak M, Topbas M.

Endocrine. 2008 Aug-Dec;34(1-3):36-51. doi: 10.1007/s12020-008-9100-z. Epub 2008 Nov 12.

PMID:
19003544
13.

Hypertriglyceridemia in different degrees of glucose intolerance in a Finnish population-based study.

Salomaa VV, Tuomilehto J, Jauhiainen M, Korhonen HJ, Stengård J, Uusitupa M, Pitkanen M, Penttila I.

Diabetes Care. 1992 May;15(5):657-65.

PMID:
1516486
14.

[Gender difference in association between smoking and metabolic risks among community adults].

Wang JW, Hu DY, Sun YH, Wang JH, Xie J.

Zhonghua Yi Xue Za Zhi. 2011 Mar 29;91(12):805-9. Chinese.

PMID:
21600158
15.
16.

[The metabolic syndrome in patients with type 1 diabetes mellitus. Associations with cardiovascular risk factors and cardiovascular morbidity].

Reindel J, Zander E, Heinke P, Kohnert KD, Allwardt C, Kerner W.

Herz. 2004 Aug;29(5):463-9. German.

PMID:
15340731
17.

Weight, the metabolic syndrome, and coronary heart disease in type 2 diabetes: associations among a national French sample of adults with diabetes-the ENTRED study.

Hillier TA, Fosse S, Balkau B, Simon D, Eschwège E, Fagot-Campagna A.

J Cardiometab Syndr. 2006 Fall;1(5):318-25.

18.

Prevalence of metabolic syndrome in the Mediterranean region of Turkey: evaluation of hypertension, diabetes mellitus, obesity, and dyslipidemia.

Gündogan K, Bayram F, Capak M, Tanriverdi F, Karaman A, Ozturk A, Altunbas H, Gökce C, Kalkan A, Yazici C.

Metab Syndr Relat Disord. 2009 Oct;7(5):427-34. doi: 10.1089/met.2008.0068.

PMID:
19754305
19.
20.

Supplemental Content

Support Center